title: Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease.
abstract: OBJECTIVE
  Epithelioid granulomas is one of the best histological criterion for distinguishing Crohn's disease (CD) from other inflammatory bowel diseases. Few data are available on the time of occurrence of epithelioid granulomas, and the value of epithelioid granulomas in predicting outcome has been determined only in cohorts of prevalent CD cases. Our objective was to evaluate epithelioid granuloma occurrence in incident CD cases and to examine the associations between epithelioid granulomas and outcome.
  
  
  METHODS
  We reviewed the histological reports of endoscopic and surgical specimens in a cohort of 188 consecutive incident CD cases seen in 1994 and 1995, and recorded the occurrence of epithelioid granulomas, isolated giant cells, and microgranulomas. Kaplan-Meier curves were plotted for time from CD diagnosis to immunosuppressive treatment or surgery, and associations between epithelioid granulomas and outcome were evaluated in a multivariate analysis. Follow up was at least five years.
  
  
  RESULTS
  Granulomas were found in 69 (37%) patients, including 46 (25%) at presentation. Median time from CD diagnosis to epithelioid granuloma detection was 0.16 (0-63) months overall, and 9.59 (0.1-63) months in 23 patients who became epithelioid granuloma positive during follow up. Isolated giant cells were found in 6% of patients and microgranulomas in 12%. Epithelioid granuloma detection increased with the number of endoscopic sampling procedures; sampling site had no influence. By multivariate analysis, epithelioid granulomas were associated with surgical resection but not immunosuppressive therapy.
  
  
  CONCLUSIONS
  Epithelioid granulomas may separate CD into two pathological subsets and may indicate aggressive disease.
authors.affiliation: ABERMAD, Pontchaillou Teaching Hospital, 35033-Rennes Cedex, France. denis.heresbach@chu-rennes.fr
authors.forename: D
authors.initials: D
authors.lastname: Heresbach
authors.forename: J L
authors.initials: JL
authors.lastname: Alexandre
authors.forename: B
authors.initials: B
authors.lastname: Branger
authors.forename: J F
authors.initials: JF
authors.lastname: Bretagne
authors.forename: E
authors.initials: E
authors.lastname: Cruchant
authors.forename: A
authors.initials: A
authors.lastname: Dabadie
authors.forename: M
authors.initials: M
authors.lastname: Dartois-Hoguin
authors.forename: P M
authors.initials: PM
authors.lastname: Girardot
authors.forename: H
authors.initials: H
authors.lastname: Jouanolle
authors.forename: J
authors.initials: J
authors.lastname: Kerneis
authors.forename: J C
authors.initials: JC
authors.lastname: Le Verger
authors.forename: V
authors.initials: V
authors.lastname: Louvain
authors.forename: J
authors.initials: J
authors.lastname: Politis
authors.forename: M
authors.initials: M
authors.lastname: Richecoeur
authors.forename: M
authors.initials: M
authors.lastname: Robaszkiewicz
authors.forename: J A
authors.initials: JA
authors.lastname: Seyrig
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D002648:Child; D003424:Crohn Disease / Q000150:complications* / Q000473:pathology / Q000628:therapy; D004812:Epidemiologic Methods; D005260:Female; D006099:Granuloma / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007410:Intestinal Diseases / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D007166:Immunosuppressive Agents